Quality

Selecting the right supplier and solution for delivering critical medications to your patients is one of the most important decisions you must make. Your practitioners and your patients are relying on you.

A 503B Quality Organization Built Around the Patient

SCA Pharmaceuticals is a registered 503B sterile compounding facility with sites in Windsor, Connecticut and Little Rock, Arkansas. Our Quality organization is structured around a single, non-negotiable premise: every vial, syringe, and bag that leaves our facilities must be safe, sterile, and clinically dependable for the patient who receives it. That premise drives every system, every decision, and every investment we make.

An independent Quality Unit with full decisional authority.

Our Quality Unit is organizationally and functionally independent of Operations. It is led by the Chief Quality Officer (CQO) reporting directly to Chief Executive Officer (CEO), and it holds final authority over the release or rejection of every batch we produce. This independence is not a cosmetic governance feature — it is the structural mechanism by which patient safety is protected from any competing commercial pressure.

Compliance is the floor, not the ceiling.

As a 503b sterile compounding facility, SCA Pharmaceuticals operates under FDA’s Current Good Manufacturing Practice expectations for sterile drug compounding, including the requirements of 21 CFR Part 211, FDA’s cGMP Guidance for Human Drug Compounding Outsourcing Facilities, and the 2004 Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. We align our Pharmaceutical Quality System with the principles of ICH Q9(R1) Quality Risk Management and ICH Q10 Pharmaceutical Quality System, and we integrate the contamination control expectations articulated in modern global aseptic processing standards. State boards of pharmacy and the relevant USP General Chapters — including <85>, <788>, <1116>, and <1223> — are embedded in the system as baseline expectations.

We treat regulatory compliance as the minimum acceptable standard. Our internal specifications and acceptance criteria are tighter than what regulation requires. Internal audit findings are resolved with the same urgency as a regulator’s. Our culture is one in which quality is everyone’s responsibility.

State-of-the-Art Laboratories Supporting Every Release

SCA Pharmaceuticals operates analytical and microbiological laboratories that support every batch we release. The laboratory infrastructure is designed for the rigor of the testing required and the speed at which our customers — and their patients — need product to be available.

Chemistry Laboratory

Our Chemistry Laboratory at the Windsor facility develops and executes stability-indicating analytical methods that meet the validation expectations of ICH Q2(R2). The laboratory performs analytical release testing on every batch of finished product, conducts the formal stability programs that support assigned Beyond Use Dates (BUDs), and supports investigations and method development through a suite of orthogonal analytical techniques. The instrumentation, methodology, and data infrastructure are selected to deliver the analytical sensitivity, specificity, and traceability that release decisions for sterile injectable medications demand.

Chromatography — Assay, Identity, and Impurity Determination. At the core of our analytical platform is a comprehensive chromatography suite that includes both High-Performance Liquid Chromatography (HPLC) and Ultra-High Performance Liquid Chromatography (UPLC). Detection capabilities include photodiode array (PDA) detection for full-spectrum UV/Vis acquisition and peak-purity confirmation, alongside complementary detection modes selected to suit method requirements. UPLC delivers the higher resolution and shorter cycle times needed for high-throughput release testing without compromising chromatographic integrity. All methods are developed against ICH Q2(R2) validation criteria and, where shelf-life determination requires it, are demonstrated to be stability-indicating.

Subvisible Particulate Matter — USP <788> Subvisible particulate matter is one of the most clinically consequential quality attributes of any injectable medication, and our analytical capability in this area is engineered accordingly. Testing is performed on state-of-the-art light obscuration instrumentation incorporating laser-based optical detection and a precision syringe-driven volumetric sampling system that enables accurate, reproducible measurement across a broad range of sample volumes. The system simultaneously quantifies particles across multiple size channels with the resolution required to meet the compendial limits of USP <788> for general parenteral injections.  Data acquisition, audit trail, and reporting are 21 CFR Part 11 compliant and integrated into our electronic data management infrastructure.

pH and Solution Characterization. pH is determined using calibrated instrumentation against NIST-traceable, multi-point buffer standards. pH is a defined release attribute for every parenteral product we compound, and its measurement is held to the same data integrity and method-control standards as any chromatographic release test.

Elemental Analysis. Atomic absorption spectroscopy supports targeted elemental analysis aligned with USP <232> and ICH Q3D considerations where relevant to a given product or raw material.

Stability Programs. Stability studies are executed in qualified Thermo and Caron environmental chambers operated under ICH Q1A(R2)-aligned conditions, with continuous temperature and relative humidity monitoring and validated alarming. Long-term, accelerated, and intermediate storage conditions are supported, along with refrigerated storage where product stability profiles require them. Every storage unit is mapped, monitored, and trended so that the data underpinning each BUD assignment is defensible to the same standard as the analytical results it supports.

Microbiology Laboratory

Our Microbiology laboratories are built around growth-based rapid microbiological technologies that compress the timeline between compounding and release without compromising the rigor of the data. Every batch we manufacture is subject to a defined battery of microbiological testing before the Quality Unit will disposition it.

Our investment in rapid microbiological technology directly supports patient access — particularly for short-dated products, where a meaningful portion of usable shelf life can be lost to the 14-day incubation of legacy compendial sterility testing.

Capabilities include:

• Celsis^® Rapid Detection System — a growth-based ATP bioluminescence platform validated as an alternative microbiological method under USP <1223>, with demonstrated comparability to the compendial USP <71> sterility test. The growth-based design preserves the regulatory rigor of compendial methodology while delivering substantially faster time to result.
• Charles River Endosafe^®-MCS — rapid bacterial endotoxin testing aligned with USP <85>.
• Rapid Micro Biosystems Growth Direct^® — automated microbial enumeration for environmental and bioburden monitoring.
• Vitek^® microbial identification — species-level identification of recoveries from environmental and personnel monitoring.

Our microbial identification program continuously characterizes the microflora recovered from our classified environments. Identification at the species level — coupled with rigorous trending — allows us to detect contamination control drift early and to take preventive action before it threatens product.

Customers can read more about our Pharmaceutical Quality System (PQS) and our Quality Standards through the links below.